There is initial evidence suggesting that among ApoE4 genotype carriers, who are at high AD risk, precision nutrition targeting metabolic pathways altered by ApoE4 provides a tool for the potential prevention of disease [16,17]. This evidence concerns the gene APOE and Alzheimer disease.